Managing Treatment for IDH2-Mutated AML

preview_player
Показать описание
Courtney D. DiNardo, MD, MSCE, describes the factors for choosing treatment, including response to chemotherapy, and the options for treatment, especially after developing relapsed acute myeloid leukemia CEBP-alpha.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Managing Treatment for 0:02:39

Managing Treatment for IDH2-Mutated AML

Treatment strategies for 0:01:53

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy

How do targeted 0:01:27

How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?

Toxicity Management in 0:05:40

Toxicity Management in the Treatment of R/R AML

Case Presentation: IDH2-Mutated 0:02:15

Case Presentation: IDH2-Mutated AML

AML: Significance of 0:02:10

AML: Significance of the IDH2 Mutation

Combining Azacitadine/Enasidenib to 0:00:50

Combining Azacitadine/Enasidenib to Enhance the Treatment of Newly Diagnosed IDH2-Mutant AML

Treatment of Patients 0:06:15

Treatment of Patients With Chemo-Refractory AML

Case Review: IDH2-Mutated 0:01:51

Case Review: IDH2-Mutated Acute Myeloid Leukemia

David Sallman, MD, 0:01:54

David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia

AML Treatment Challenges 0:18:29

AML Treatment Challenges Who, When, and How

IDH inhibitors for 0:01:32

IDH inhibitors for AML and MDS

The impact of 0:04:51

The impact of IDH mutated clones in NPM1+ AML

Maintenance and Continuous 0:04:33

Maintenance and Continuous Treatment in Acute Myeloid Leukemia

What are the 0:04:02

What are the strategies for patients who have relapsed? #AML

Venetoclax plus HMAs 0:05:35

Venetoclax plus HMAs in IDH-mutant AML

FLT3 Mutations’ Impact 0:06:43

FLT3 Mutations’ Impact on Prognosis and Treatment in AML

Phase II trial 0:02:01

Phase II trial of enasidenib in IDH2-mutant MDS

Rationale for Enasidenib 0:03:05

Rationale for Enasidenib in AML

Enasidenib in mIDH 0:04:02

Enasidenib in mIDH relapsed and refractory AML

IDH inhibitors in 0:42:38

IDH inhibitors in relapsed/refractory AML

Which R/R AML 0:01:51

Which R/R AML subgroups would benefit from enasidenib treatment?

IDH Mutations in 0:06:14

IDH Mutations in AML

Treating patients with 0:07:20

Treating patients with Enasidenib or Ivosidenib: Managing IDH-DS & other Clinical Pearls

visit shbcf.ru